Next Article in Journal
HumiR: Web Services, Tools and Databases for Exploring Human microRNA Data
Next Article in Special Issue
Cannabinoid Receptor Interacting Protein 1a (CRIP1a) in Health and Disease
Previous Article in Journal
Polyphenol Extract from Evening Primrose (Oenothera paradoxa) Inhibits Invasion Properties of Human Malignant Pleural Mesothelioma Cells
Previous Article in Special Issue
Gene Expression Analysis of Astrocyte and Microglia Endocannabinoid Signaling during Autoimmune Demyelination
Open AccessReview

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

1
Neurosciences Institute, University Miguel Hernández-CSIC, Avda de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain
2
Subject Area Network of Cooperative Health Research (RETICS), Network for Addiction Disorders, Health Institute Carlos III, MICINN and FEDER, 28029 Madrid, Spain
*
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(11), 1575; https://doi.org/10.3390/biom10111575
Received: 18 September 2020 / Revised: 17 November 2020 / Accepted: 18 November 2020 / Published: 19 November 2020
(This article belongs to the Special Issue The Endocannabinoid System in Health and Disease)
The potential therapeutic use of some Cannabis sativa plant compounds has been attracting great interest, especially for managing neuropsychiatric disorders due to the relative lack of efficacy of the current treatments. Numerous studies have been carried out using the main phytocannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD displays an interesting pharmacological profile without the potential for becoming a drug of abuse, unlike THC. In this review, we focused on the anxiolytic, antidepressant, and antipsychotic effects of CBD found in animal and human studies. In rodents, results suggest that the effects of CBD depend on the dose, the strain, the administration time course (acute vs. chronic), and the route of administration. In addition, certain key targets have been related with these CBD pharmacological actions, including cannabinoid receptors (CB1r and CB2r), 5-HT1A receptor and neurogenesis factors. Preliminary clinical trials also support the efficacy of CBD as an anxiolytic, antipsychotic, and antidepressant, and more importantly, a positive risk-benefit profile. These promising results support the development of large-scale studies to further evaluate CBD as a potential new drug for the treatment of these psychiatric disorders. View Full-Text
Keywords: cannabidiol; depressive disorders; PTSD; anxiety disorders; schizophrenia; clinical trials; animal studies cannabidiol; depressive disorders; PTSD; anxiety disorders; schizophrenia; clinical trials; animal studies
Show Figures

Figure 1

MDPI and ACS Style

García-Gutiérrez, M.S.; Navarrete, F.; Gasparyan, A.; Austrich-Olivares, A.; Sala, F.; Manzanares, J. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules 2020, 10, 1575.

AMA Style

García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules. 2020; 10(11):1575.

Chicago/Turabian Style

García-Gutiérrez, María S.; Navarrete, Francisco; Gasparyan, Ani; Austrich-Olivares, Amaya; Sala, Francisco; Manzanares, Jorge. 2020. "Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders" Biomolecules 10, no. 11: 1575.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop